Clinical Trial: Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma

U.S., Sept. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07174427) titled 'Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma' on Sept. 12.

Brief Summary: The purpose of this study is to verify the safety and the efficacy of TBI-1301 for NY-ESO-1 expressing synovial sarcoma when administered following cyclophosphamide/fludarabine pre-treatment.

Study Start Date: Nov., 2025

Study Type: INTERVENTIONAL

Condition: Synovial Sarcomas

Intervention: BIOLOGICAL: TBI-1301

Split dose of TBI-1301 is administered intravenously for 2 days following cyclophosphamide/fludarabine pre-treatment.

DRUG: Cyclophosphamide

Cyclophosphamide (750mg/m...